SYMBIOTEC PHARMALAB (SYMBIOTEC) 52 Week High Streak: Second Straight Session
- October 1, 2026
- Posted by: Kunal Singla
- Category: News
SYMBIOTEC PHARMALAB LTD has now set a fresh 52-week high for its second straight session, and the cumulative move across this streak stands at 2.58%. The latest peak is Rs 1,198.95, while the stock last traded at Rs 1,173.90.
At 01 October 2026 at 9:22 AM IST, the stock was trading below the previous close of Rs 1,176.05 after opening at Rs 1,197.80 and touching a low of Rs 1,168.80. Turnover and market capitalisation place the move in a wider market context, but the key point for readers is different from a one-day breakout: SYMBIOTEC 52 Week High Streak now reflects a two-session sequence of new yearly highs rather than a single intraday print.
SYMBIOTEC PHARMALAB LTD 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,173.9 |
| Previous Close | Rs 1,176.05 |
| Today's Move | Rs -2.15 (-0.18%) |
| Open | Rs 1,197.8 |
| High | Rs 1,198.95 |
| Low | Rs 1,168.8 |
| Market Capitalisation | Rs 7,353.15 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) traded at Rs 1,173.9 versus the previous close of Rs 1,176.05, a fall of 0.18%. The stock opened at Rs 1,197.8, reached a high of Rs 1,198.95 and touched a low of Rs 1,168.8.
SYMBIOTEC PHARMALAB LTD was last traded at Rs 1,173.90, down Rs 2.15 or 0.18% versus the previous close of Rs 1,176.05. The stock opened at Rs 1,197.80, touched a high of Rs 1,198.95 and a low of Rs 1,168.80, with the latest price standing nearer the lower end of that range. This is the same level as the fresh 52-week high for the session, so the intraday peak and the yearly peak are aligned. Market capitalisation stood at Rs 7,353.15 crore, which gives scale to the move without saying anything about quality on its own. For readers tracking SYMBIOTEC 52 Week High Streak, the important detail is that the stock has repeated the yearly-high pattern across two sessions while the latest price remained only slightly below the prior close.
SYMBIOTEC PHARMALAB LTD 52 Week High Streak: Consecutive High Analysis
SYMBIOTEC PHARMALAB LTD’s 52 Week High Streak is now a second straight session event, and that matters because it shows continuity rather than a one-off print. The cumulative rise of 2.58% across the streak is the clearest measure of how far the stock has moved over these consecutive sessions. In practical terms, the current fresh 52-week high of Rs 1,198.95 is not just a single-session marker; it is the top of a two-day sequence that began on 30 September 2026 and repeated on the next trading session.
The latest Univest figures show a narrow daily move on the latest session even as the yearly-high pattern continued. That mix is useful for readers following SYMBIOTEC 52 Week High Streak: the stock did not need a large single-day jump to keep setting new peaks.
What the Repeated 52-Week Highs Show
Repeated yearly highs tell a different story from an isolated breakout because they show that the stock has held above its prior peak for more than one session. In this case, SYMBIOTEC 52 Week High Streak points to a short run where the market has kept the price near a new one-year top instead of slipping back immediately below it. The cumulative gain matters here because it captures the full streak, not just the latest tick.
Latest News Around SYMBIOTEC PHARMALAB LTD (SYMBIOTEC)
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 7,353.15 crore |
| P/E Ratio | 68.76x |
| P/B Ratio | 5.04x |
| ROE | 11.22% |
| ROCE | 12.41% |
| EPS | Rs 17.1 |
| Book Value Per Share | Rs 233.38 |
| Dividend Yield | 0% |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 68.76x, P/B 5.04x, ROE 11.22%, ROCE 12.41%. Taken on their own, these numbers offer context rather than a trading signal.
SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 7,353.15 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 68.76x, P/B at 5.04x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 233.38, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.01x, median ROE of 11.74%, median ROCE of 13.63%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 68.76x |
| Benchmark Median P/E | 32.01x |
| Benchmark Average P/E | 49.06x |
| Benchmark P/E Range | 3.4x to 688.17x |
| Company P/B Ratio | 5.04x |
| Benchmark Median P/B | 2.92x |
| Company ROE | 11.22% |
| Benchmark Median ROE | 11.74% |
| Company ROCE | 12.41% |
| Benchmark Median ROCE | 13.63% |
| Company Market Capitalisation | Rs 7,353.15 crore |
| Benchmark Median Market Cap | Rs 765.11 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 68.76x, which is above the benchmark median of 32.01x, a difference of +114.81%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.74%, a difference of -4.43%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.63%, a difference of -8.95%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Innova Captab Ltd. | INNOVACAP | 7,282.44 | 42.4 | 5.84 | 13.75 | 15.04 |
| Bliss GVS Pharma Ltd. | BLISSGVS | 7,550 | 54.29 | 6 | 12.11 | 17.4 |
| Sanofi India Ltd. | SANOFI | 7,072.59 | 21.76 | 8.53 | 44.5 | 55.46 |
| Supriya Lifescience Ltd. | SUPRIYA | 7,652.71 | 38.58 | 6.26 | 19.06 | 25.3 |
| Morepen Laboratories Ltd. | MOREPENLAB | 6,509.69 | 49.13 | 5.3 | 7.96 | 10.19 |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 68.76x compared with the displayed peer median of 42.4x. The comparison is relative and should not be read as a recommendation. Its ROE of 11.22% compares with a peer median of 13.75% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 17.4%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 7,353.15 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching SYMBIOTEC PHARMALAB LTD
- SYMBIOTEC 52 Week High Streak is now two sessions long, which makes the pattern more persistent than a single breakout.
- The cumulative move across the streak is 2.58%, giving a clearer read on the full run than today’s small change alone.
- The latest 52-week high of Rs 1,198.95 is the same as the session high, which keeps the yearly-high pattern intact.
- The stock’s P/E of 68.76 now sits well above the industry median after the streak move.
About SYMBIOTEC PHARMALAB LTD
SYMBIOTEC PHARMALAB LTD operates in the Pharmaceuticals & Drugs industry within Healthcare, and the current SYMBIOTEC 52 Week High Streak puts that business profile in immediate market focus. The company’s market capitalisation is Rs 7,353.15 crore, which places it among the better-known names in the industry set being tracked here. The current move should be read through the lens of price, valuation and sector comparison rather than as a broad business commentary.
For readers, the useful business context is that the company has a market-facing presence large enough to be compared with other listed pharmaceutical names in the same industry, while the streak has lifted the valuation discussion to the centre of the narrative. That is why SYMBIOTEC 52 Week High Streak matters: it changes the way the market is pricing the company even when the business description itself is unchanged.
Track SYMBIOTEC PHARMALAB LTD on Univest
Follow SYMBIOTEC PHARMALAB LTD on Univest to watch how the fresh 52-week high streak develops from here. The current focus is on whether the stock can keep trading near its yearly high, how the valuation compares with industry peers, and whether the next sessions extend the run or narrow it. SYMBIOTEC 52 Week High Streak remains the key theme for readers tracking the stock.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
How many sessions has SYMBIOTEC PHARMALAB LTD been at a fresh 52-week high?
Ans. SYMBIOTEC PHARMALAB LTD has now set a fresh 52-week high for its second straight session. That makes the current event a two-session SYMBIOTEC 52 Week High Streak rather than a single-day breakout.
What is the cumulative move across the SYMBIOTEC 52 Week High Streak?
Ans. The cumulative move across the streak is 2.58%. That figure captures the full two-session run and is more useful here than looking only at the latest intraday change.
What is the latest 52-week high for SYMBIOTEC PHARMALAB LTD?
Ans. The latest 52-week high is Rs 1,198.95. In the current session, that level also matched the intraday high, so the yearly peak and session peak were the same.
How did SYMBIOTEC PHARMALAB LTD trade around the prior close?
Ans. The stock last traded at Rs 1,173.90 versus the previous close of Rs 1,176.05, a decline of Rs 2.15 or 0.18%. The move was modest, even though the broader streak remained intact.
Did the latest data confirm a company-specific catalyst?
Ans.A recent partnership report involving the subsidiary Knovea may be relevant, but the price pattern itself does not prove causation.
How does SYMBIOTEC compare with the industry on valuation?
Ans. Its P/E of 68.76 is above the industry median of 32.01, while its P/B of 5.04 is above the industry median of 2.92. After the streak, the stock is valued richer than the middle of the industry set.
What should investors monitor next in SYMBIOTEC 52 Week High Streak?
Ans. Investors can monitor whether the stock keeps holding near the new yearly high, how the valuation compares with peers after each session, and whether any fresh business update aligns with the repeated-high pattern.
Why is the repeated 52-week high more important than a one-day breakout?
Ans. A repeated high shows that the stock has reset its yearly peak on more than one session. That makes the move more informative for readers tracking SYMBIOTEC 52 Week High Streak than a single intraday print would be.
Track SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Share Price on Univest
Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
